NR546 ADVANCED PSYCHOPHARMACOLOGY
MIDTERM EXAM / ACTUAL EXAM QUESTIONS AND
CORRECT VERIFIED ANSWERS WITH RATIONALES
CHAMBERLAIN UNIVERSITY
100% GUARANTEED PASS!!
<LATEST VERSION>
1. A psychiatric mental health nurse practitioner reviews the four major processes
that determine the concentration of a psychotropic medication over time. Which
process describes the movement of a drug from the gastrointestinal tract into
systemic circulation?
A. Distribution
B. Absorption
C. Metabolism
D. Excretion
Answer: B
Rationale: Absorption is the movement of a drug from its site of administration
into the systemic circulation. Route of administration, gastrointestinal motility,
blood flow, formulation, food, and other factors can influence absorption.
Distribution describes movement of drug throughout body tissues; metabolism
involves chemical modification of the drug, often in the liver; and excretion refers
primarily to removal through the kidneys, although other routes contribute.
,2. A medication has an elimination half-life of 12 hours. Under normal dosing
conditions, approximately how long should the PMHNP expect it to take for the
medication to reach near steady-state concentrations?
A. 12 hours
B. 24 hours
C. 48–60 hours
D. 120–144 hours
Answer: C
Rationale: Most medications require approximately 4–5 elimination half-lives to
approach steady state. For a half-life of 12 hours, 4–5 half-lives correspond to
approximately 48–60 hours. Increasing the dose does not substantially shorten the
time required to reach steady state; a loading dose can increase concentrations
more rapidly when clinically appropriate.
3. During medication counseling, a patient asks why a highly protein-bound
medication may require closer monitoring when serum albumin becomes markedly
reduced. Which pharmacokinetic principle best explains the concern?
A. Reduced albumin can increase the unbound fraction of the medication
B. Reduced albumin always decreases gastrointestinal absorption
C. Reduced albumin prevents hepatic metabolism completely
D. Reduced albumin increases renal tubular secretion of all medications
Answer: A
Rationale: Many medications circulate partly bound to plasma proteins such as
albumin. The unbound fraction is generally available to leave the bloodstream,
reach tissues, and exert pharmacologic effects. When albumin concentrations
decrease, highly protein-bound drugs may have a greater free fraction, potentially
increasing clinical effects or toxicity. The relationship varies by medication,
clinical condition, and clearance mechanism, so therapeutic monitoring must be
individualized.
,4. A patient who has been stable on an antipsychotic develops increased sedation
and other adverse effects shortly after fluoxetine is added for depression. The
antipsychotic is substantially metabolized by CYP2D6. Which mechanism most
likely accounts for the change?
A. Fluoxetine induces CYP2D6 and accelerates antipsychotic clearance
B. Fluoxetine inhibits CYP2D6 and reduces antipsychotic clearance
C. Fluoxetine increases renal excretion of the antipsychotic
D. Fluoxetine blocks gastrointestinal absorption of the antipsychotic
Answer: B
Rationale: Fluoxetine is a clinically important CYP2D6 inhibitor. Inhibition of a
metabolic enzyme can reduce clearance of a substrate medication, resulting in
increased drug exposure and potentially greater adverse effects. This is a
pharmacokinetic drug interaction because one medication changes the
concentration of another by altering its metabolism.
5. A patient with schizophrenia has achieved symptom control on clozapine while
smoking one pack of cigarettes daily. The patient abruptly stops smoking. Which
change should the PMHNP anticipate?
A. Increased CYP1A2 activity with lower clozapine concentrations
B. Decreased CYP1A2 induction with potentially increased clozapine
concentrations
C. Increased renal clearance with lower clozapine concentrations
D. Reduced clozapine absorption caused by nicotine withdrawal
Answer: B
Rationale: Combustion products in tobacco smoke induce CYP1A2, which
contributes to the metabolism of clozapine. When a patient stops smoking, that
enzyme-inducing effect decreases. Clozapine exposure may therefore rise,
increasing the risk of dose-related adverse effects. The PMHNP should recognize
smoking status as an important variable when initiating, adjusting, or monitoring
clozapine therapy.
, 6. Which statement best describes a partial agonist?
A. It binds a receptor but produces no biologic activity
B. It produces maximal receptor activity regardless of dose
C. It produces less than maximal receptor activation and may oppose a full agonist
when both are present
D. It permanently blocks receptor signaling through irreversible binding
Answer: C
Rationale: A partial agonist has receptor affinity but produces submaximal
intrinsic activity even when occupying a large proportion of receptors. In an
environment with high concentrations of an endogenous full agonist, a partial
agonist can reduce overall receptor activation by competing for the same receptors.
In an environment with little endogenous agonist activity, it can provide some
receptor stimulation.
7. A pharmacology examination asks the PMHNP to distinguish receptor ligands
according to their effects on constitutive receptor activity. Which ligand decreases
receptor activity below its normal baseline level?
A. Full agonist
B. Partial agonist
C. Neutral antagonist
D. Inverse agonist
Answer: D
Rationale: An inverse agonist decreases constitutive receptor activity below its
baseline level. A neutral antagonist blocks receptor activation by an agonist but has
no intrinsic activity of its own. A full agonist produces maximal activation,
whereas a partial agonist produces less than maximal activation.
MIDTERM EXAM / ACTUAL EXAM QUESTIONS AND
CORRECT VERIFIED ANSWERS WITH RATIONALES
CHAMBERLAIN UNIVERSITY
100% GUARANTEED PASS!!
<LATEST VERSION>
1. A psychiatric mental health nurse practitioner reviews the four major processes
that determine the concentration of a psychotropic medication over time. Which
process describes the movement of a drug from the gastrointestinal tract into
systemic circulation?
A. Distribution
B. Absorption
C. Metabolism
D. Excretion
Answer: B
Rationale: Absorption is the movement of a drug from its site of administration
into the systemic circulation. Route of administration, gastrointestinal motility,
blood flow, formulation, food, and other factors can influence absorption.
Distribution describes movement of drug throughout body tissues; metabolism
involves chemical modification of the drug, often in the liver; and excretion refers
primarily to removal through the kidneys, although other routes contribute.
,2. A medication has an elimination half-life of 12 hours. Under normal dosing
conditions, approximately how long should the PMHNP expect it to take for the
medication to reach near steady-state concentrations?
A. 12 hours
B. 24 hours
C. 48–60 hours
D. 120–144 hours
Answer: C
Rationale: Most medications require approximately 4–5 elimination half-lives to
approach steady state. For a half-life of 12 hours, 4–5 half-lives correspond to
approximately 48–60 hours. Increasing the dose does not substantially shorten the
time required to reach steady state; a loading dose can increase concentrations
more rapidly when clinically appropriate.
3. During medication counseling, a patient asks why a highly protein-bound
medication may require closer monitoring when serum albumin becomes markedly
reduced. Which pharmacokinetic principle best explains the concern?
A. Reduced albumin can increase the unbound fraction of the medication
B. Reduced albumin always decreases gastrointestinal absorption
C. Reduced albumin prevents hepatic metabolism completely
D. Reduced albumin increases renal tubular secretion of all medications
Answer: A
Rationale: Many medications circulate partly bound to plasma proteins such as
albumin. The unbound fraction is generally available to leave the bloodstream,
reach tissues, and exert pharmacologic effects. When albumin concentrations
decrease, highly protein-bound drugs may have a greater free fraction, potentially
increasing clinical effects or toxicity. The relationship varies by medication,
clinical condition, and clearance mechanism, so therapeutic monitoring must be
individualized.
,4. A patient who has been stable on an antipsychotic develops increased sedation
and other adverse effects shortly after fluoxetine is added for depression. The
antipsychotic is substantially metabolized by CYP2D6. Which mechanism most
likely accounts for the change?
A. Fluoxetine induces CYP2D6 and accelerates antipsychotic clearance
B. Fluoxetine inhibits CYP2D6 and reduces antipsychotic clearance
C. Fluoxetine increases renal excretion of the antipsychotic
D. Fluoxetine blocks gastrointestinal absorption of the antipsychotic
Answer: B
Rationale: Fluoxetine is a clinically important CYP2D6 inhibitor. Inhibition of a
metabolic enzyme can reduce clearance of a substrate medication, resulting in
increased drug exposure and potentially greater adverse effects. This is a
pharmacokinetic drug interaction because one medication changes the
concentration of another by altering its metabolism.
5. A patient with schizophrenia has achieved symptom control on clozapine while
smoking one pack of cigarettes daily. The patient abruptly stops smoking. Which
change should the PMHNP anticipate?
A. Increased CYP1A2 activity with lower clozapine concentrations
B. Decreased CYP1A2 induction with potentially increased clozapine
concentrations
C. Increased renal clearance with lower clozapine concentrations
D. Reduced clozapine absorption caused by nicotine withdrawal
Answer: B
Rationale: Combustion products in tobacco smoke induce CYP1A2, which
contributes to the metabolism of clozapine. When a patient stops smoking, that
enzyme-inducing effect decreases. Clozapine exposure may therefore rise,
increasing the risk of dose-related adverse effects. The PMHNP should recognize
smoking status as an important variable when initiating, adjusting, or monitoring
clozapine therapy.
, 6. Which statement best describes a partial agonist?
A. It binds a receptor but produces no biologic activity
B. It produces maximal receptor activity regardless of dose
C. It produces less than maximal receptor activation and may oppose a full agonist
when both are present
D. It permanently blocks receptor signaling through irreversible binding
Answer: C
Rationale: A partial agonist has receptor affinity but produces submaximal
intrinsic activity even when occupying a large proportion of receptors. In an
environment with high concentrations of an endogenous full agonist, a partial
agonist can reduce overall receptor activation by competing for the same receptors.
In an environment with little endogenous agonist activity, it can provide some
receptor stimulation.
7. A pharmacology examination asks the PMHNP to distinguish receptor ligands
according to their effects on constitutive receptor activity. Which ligand decreases
receptor activity below its normal baseline level?
A. Full agonist
B. Partial agonist
C. Neutral antagonist
D. Inverse agonist
Answer: D
Rationale: An inverse agonist decreases constitutive receptor activity below its
baseline level. A neutral antagonist blocks receptor activation by an agonist but has
no intrinsic activity of its own. A full agonist produces maximal activation,
whereas a partial agonist produces less than maximal activation.
